Oryzon Genomics SA Alternatives & Competitors
12 companies similar to Oryzon Genomics SA — Pioneering personalized medicine in epigenetics
Companies similar to Oryzon Genomics SA
Cleave Therapeutics, Inc.
VCP/p97 Inhibitors for Oncology and Neurodegenerative Diseases
San Francisco, United Sta...
Oxford BioDynamics Plc
Advancing personalized healthcare by developing and commercializing precision medicine tes...
Oxford, United Kingdom
GT Biopharma, Inc.
Focused on the next generation of immunotherapies by leveraging our proprietary TriKE plat...
Brisbane, United States
Avenzo Therapeutics
Developing the next generation of oncology therapies for patients
San Diego, United States
Rival Readout
Competing with Oryzon Genomics SA? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Chordia Therapeutics Inc
We are passionate to deliver first in class cancer drugs to patients from Japan.
Fujisawa, Japan
Lynx Biosciences, Inc.
Resolving cancer biology through integrated multi-omics.
San Diego, United States
GLG Pharma
Why Show the GSK Compound? Because the cancer cells become resistant. How? By STAT3! GLG's...
Jupiter, United States
Cytovas
Empowering precision medicine through a pioneering cell-based informatics platform, delive...
Pathos
AI-enabled drug development built for patients
Chicago, United States
-Corp.-logo.jpg "SyneuRx International (Taiwan) Corp."){kind=logo}
SyneuRx International (Taiwan) Corp.
Developing new classes of drugs for COVID-19 and multiple major central nervous system dis...
Taiwan
Ariceum Therapeutics
Developing next-generation radiotherapeutics to visualize and treat cancer
Berlin, Germany
About Oryzon Genomics SA
Oryzon Genomics SA, founded in 2000 and headquartered in Spain, is a clinical stage biopharmaceutical leader in the development of epigenetics-based therapeutics, with an emphasis on personalized medicine for CNS disorders and oncology. Known for its slogan, "Pioneering personalized medicine in epigenetics," the compan...
Development of personalized therapeutics, Epigenetic biomarker identification, Innovation in cancer and CNS disorder treatments, Patent portfolio management
Patients with cancer, Patients with CNS disorders, Healthcare providers, Biopharmaceutical investors
Personalized Medicine, Epigenetics, CNS Disorders, Oncology, Biopharmaceuticals, LSD1 Inhibitors, Biomarker Identification, Target Validation, Acute Myeloid Leukemia, Small Cell Lung Cancer, Phase II Clinical Trials, Psychiatric Diseases, Neurodegeneration, Drug Discovery, Therapeutic Development
B2B, B2D
Licensing, Performance Based
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Oryzon Genomics SA: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Oryzon Genomics SA on 26 Mar 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
